Bayer, Bristol-Myers Squibb and Ono Pharmaceutical teamed up to study the most common type of metastatic colorectal cancer.
The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
In seeking innovative players that could change pharma and healthcare, Med Ad News found the developer of an app that helps people determine what illnesses are in their neighborhoods; the creator of a wearable injector that allows patients on biologics to receive these drugs outside the clinic; and a designer of a deep learning network aimed at giving pharma and healthcare companies a handle on their data.
The top performers of the launch class of 2016 have very little in common – aside from the fact that none of them came from a “classic” big pharma house.
Copenhagen, Denmark-based Genmab A/S raised $506 million with an initial public offering (IPO), with the company trading on the Nasdaq under the ticker symbol GMAB.
New rules went into effect during 2018 on the Hong Kong stock exchange allowing companies that did not have a product on the market or generate revenue to list on the exchange.
Inovio Pharmaceuticals is terminating 28 percent of the company’s workforce, and Amneal Pharmaceuticals will cut 550 employees by the end of 2020.
Three U.S. senators introduced a resolution in support of a moratorium and other limits on gene editing embryos.
In a deal-making morning for South San Francisco-based Genentech, the Roche subsidiary struck three separate transactions with small companies to boost drug development.
Companies continue to announce advancements in artificial intelligence programming as they harness the power of AI and machine learning to aid in drug discovery and development.
Despite numerous FDA approvals of biosimilars, they have not yet gained a significant stake in the U.S. marketplace, according to a recent analysis published in Forbes.
Gilead Sciences Inc. announced that Christi L. Shaw will join the company as CEO of subsidiary Kite Pharma and will become a member of Gilead’s senior leadership team.
Reckitt Benckiser Group agreed to pay $1.4 billion to settle a U.S. investigation into the sales and marketing of Suboxone Film, a product managed by the spinout company Indivior.